Zacks: Brokerages Anticipate Bio-Path Holdings, Inc. (NASDAQ:BPTH) Will Announce Earnings of -$0.32 Per Share

Brokerages expect that Bio-Path Holdings, Inc. (NASDAQ:BPTH) will report earnings per share (EPS) of ($0.32) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Bio-Path’s earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.29). Bio-Path reported earnings per share of ($0.57) in the same quarter last year, which would suggest a positive year-over-year growth rate of 43.9%. The business is expected to report its next quarterly earnings results on Wednesday, March 9th.

According to Zacks, analysts expect that Bio-Path will report full year earnings of ($1.28) per share for the current fiscal year, with EPS estimates ranging from ($1.31) to ($1.25). For the next year, analysts anticipate that the business will post earnings of ($1.40) per share, with EPS estimates ranging from ($1.40) to ($1.39). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Bio-Path.

Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings results on Friday, November 12th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. During the same quarter last year, the firm earned ($0.80) earnings per share.

BPTH has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Bio-Path in a report on Monday, November 15th. Zacks Investment Research upgraded shares of Bio-Path from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a report on Wednesday.

NASDAQ:BPTH opened at $3.94 on Friday. The stock has a market capitalization of $28.24 million, a price-to-earnings ratio of -2.54 and a beta of 1.65. The firm has a fifty day simple moving average of $4.28 and a two-hundred day simple moving average of $5.23. Bio-Path has a 12 month low of $3.72 and a 12 month high of $24.34.

A number of institutional investors have recently added to or reduced their stakes in BPTH. Vanguard Group Inc. boosted its holdings in Bio-Path by 76.2% during the second quarter. Vanguard Group Inc. now owns 218,992 shares of the company’s stock worth $1,460,000 after purchasing an additional 94,703 shares during the last quarter. Morgan Stanley boosted its holdings in Bio-Path by 1,976.2% during the first quarter. Morgan Stanley now owns 39,966 shares of the company’s stock worth $281,000 after purchasing an additional 38,041 shares during the last quarter. Northern Trust Corp purchased a new position in Bio-Path during the second quarter worth about $119,000. State Street Corp purchased a new position in Bio-Path during the second quarter worth about $81,000. Finally, Dimensional Fund Advisors LP boosted its holdings in Bio-Path by 58.8% during the second quarter. Dimensional Fund Advisors LP now owns 28,148 shares of the company’s stock worth $188,000 after purchasing an additional 10,423 shares during the last quarter. Institutional investors and hedge funds own 6.06% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

See Also: How to Invest in a Bull Market

Get a free copy of the Zacks research report on Bio-Path (BPTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.